XNAS · Healthcare · Biotechnology
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
**Nasdaq delisting notice** threatens clinical-stage T-cell therapy developer despite strong **$0.07 EPS beat**. Annual meeting compliance failure overshadows financial progress.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | Q1 2026 | -0.12 | -0.05 | +58.33% | $0 | ✅ Beat | +3.60% | +2.68% | — |
| 2026-03-18 | Q4 2025 | -0.12 | -0.01 | +91.67% | $0 | ✅ Beat | +0.00% | -9.24% | +74.07% |
| 2025-11-12 |
| Q3 2025 |
| — |
| -0.13 |
| — |
| $0 |
| — |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.11 | -0.15 | -36.36% | $0 | ❌ Miss | -1.73% | +6.36% | +20.23% |
| 2024-09-27 | Q4 2024 | — | -0.13 | — | $0 | — | -2.52% | -3.36% | -26.05% |
| 2024-05-15 | Q3 2024 | — | -0.01 | — | $0 | — | -2.78% | -6.02% | -12.96% |
| 2024-02-14 | Q2 2024 | — | -0.03 | — | $0 | — | — | — | — |
Showing last 7 quarters.